CN104387371A - 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 - Google Patents
2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 Download PDFInfo
- Publication number
- CN104387371A CN104387371A CN201410583377.4A CN201410583377A CN104387371A CN 104387371 A CN104387371 A CN 104387371A CN 201410583377 A CN201410583377 A CN 201410583377A CN 104387371 A CN104387371 A CN 104387371A
- Authority
- CN
- China
- Prior art keywords
- methyl
- derivative
- reaction
- grams
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 title description 5
- 238000003786 synthesis reaction Methods 0.000 title description 5
- BBGKKWJDHOAKFM-UHFFFAOYSA-N 2-[(2-methyl-1h-indol-3-yl)methyl]-1h-benzimidazole Chemical class C1=CC=C2NC(CC=3C4=CC=CC=C4NC=3C)=NC2=C1 BBGKKWJDHOAKFM-UHFFFAOYSA-N 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- QJNNHJVSQUUHHE-UHFFFAOYSA-N 2-Methylindole-3-acetic acid Chemical compound C1=CC=C2C(CC(O)=O)=C(C)NC2=C1 QJNNHJVSQUUHHE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000005855 radiation Effects 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims description 3
- -1 ethylene glycol bisthioglycolate methyl esters Chemical class 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 9
- 239000002904 solvent Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 2
- 230000035484 reaction time Effects 0.000 claims 2
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 claims 1
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 claims 1
- 229920000137 polyphosphoric acid Polymers 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 150000004987 o-phenylenediamines Chemical class 0.000 abstract 2
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 abstract 2
- 101100448208 Human herpesvirus 6B (strain Z29) U69 gene Proteins 0.000 abstract 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 229960000935 dehydrated alcohol Drugs 0.000 description 8
- 239000010813 municipal solid waste Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000012265 solid product Substances 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- DGRGLKZMKWPMOH-UHFFFAOYSA-N 4-methylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1 DGRGLKZMKWPMOH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 0 Cc1c(CC(O)=O)c2c(*)c(*)c(*)c(*)c2[n]1 Chemical compound Cc1c(CC(O)=O)c2c(*)c(*)c(*)c(*)c2[n]1 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
以吲哚羧酸衍生物和邻苯二胺及其衍生物为原料发生环合反应,生成亚甲基连接的吲哚-苯并咪唑衍生物的方法。以2-甲基-3-吲哚乙酸及其衍生物和邻苯二胺及其衍生物为原料在缩合剂作用下加热或者在微波辐射下环合生成亚甲基连接的吲哚-苯并咪唑衍生物,其化学结构如下。式中取代基R1、R2、R3、R4、R5、R6、R7、R8可以是H,F,Cl,Br,CF3,CCl3,CN,N(CH3)2,N(C2H5)2,NO2,SO3H,CH2R’,OR’,NHR’,COR’,COOR’,CONHR’;其中R’为H,CH3,CH2CH3,COCH3,F,Cl,Br,CF3,CCl3。该反应条件较温和,操作较简便,产率较高。
Description
技术领域:
本发明属于新型吲哚苯并咪唑衍生物及其合成方法,以2-甲基-3-吲哚乙酸及其衍生物和邻苯二胺及其衍生物为原料发生环合反应,生成亚甲基连接的吲哚-苯并咪唑衍生物。
背景技术:
杂环化合物是有机化学重要的组成部分,是一类非常重要的有机化合物,其在生物化工、日化、医药、材料等诸多方面具有广泛的应用,如吲哚衍生物舒尼替尼(sunitinib)具有良好抗肿瘤作用,苯并咪唑衍生物咪唑斯汀和阿司咪唑具有治疗过敏性鼻炎的作用。含有吲哚连接的苯并咪唑片段的药物研究已成为医药研发十分活跃的领域之一。近年来,有文献报道了一些有关吲哚衍生物和苯并咪唑衍生物的合成、特性及生物活性。许多研究表明,含有吲哚或苯并咪唑结构片段的化合物具有有效的抗癌活性,因此亚甲基连接的吲哚-苯并咪唑作为抗癌药物具有可开发潜力,其应用前景。本发明在参考前人合成方法(王陆瑶,田敏,李晓娟,史真,微波辐射下几种特殊的2-取代苯并咪唑的合成,化学通报,2005,86:w033)基础上,合成了一系列新型亚甲基连接的吲哚-苯并咪唑衍生物。
发明内容:
本发明提供了亚甲基连接的吲哚-苯并咪唑的新合成方法,其中的某些产物为重要的药物合成中间体或者药物先导化合物。
本发明所涉及的化合物具有如下结构通式:
式中取代基R1、R2、R3、R4、R5、R6、R7、R8可以是-H,-F,-Cl,-Br,-CF3,-CCl3,-CN,-N(CH3)2,-N(C2H5)2,-NO2,-SO3H,-CH2R’,-OR’,-NHR’,-COR’,-COOR’,-CONHR’;其中R’为-H,-CH3,-CH2CH3,-COCH3,-F,-Cl,-Br,-CF3,-CCl3。
本发明方法是以2-甲基-3-吲哚乙酸及其衍生物和邻苯二胺及其衍生物为原料在缩合剂作用下加热或者在微波辐射下环合生成亚甲基连接的吲哚-苯并咪唑衍生物。
具体实施方式
通过下述实施例将有助于理解本发明,但并不限制本发明的内容。
实施例1:在三口烧瓶中先加入50毫升二甲基甲酰胺,然后依次加入4-甲基邻苯二胺7.9克,2-甲基-3-吲哚乙酸8.3克,羰基二咪唑7.1克,缓慢升温至150℃,回流反应3小时,再加入5毫升三乙胺,加热反应半小时。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得到褐色固体,用无水乙醇重结晶,过滤,滤液旋蒸,干燥后得5-甲基-2-(2-甲基-3-吲哚基)甲基苯并咪唑10.4克,产率为86%。
实施例2:在三口烧瓶中先加入50毫升二甲基甲酰胺,然后依次加入4-甲基邻苯二胺7.9克,2-甲基-3-吲哚乙酸8.3克,羰基二咪唑7.1克,置于微波反应器中,在400W功率下反应15分钟,再加入5毫升三乙胺,微波辐射反应2分钟。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得到褐色固体,用无水乙醇重结晶,得5-甲基-2-(2-甲基-3-吲哚基)甲基苯并咪唑11.2克,产率为93%。
实施例3:在三口烧瓶中加入50毫升二甲基甲酰胺,依次加入3,4-二氨基苯甲酸乙酯11.0克,2-甲基-3-吲哚乙酸8.3克,羰基二咪唑7.1克,升温至160℃,反应3小时,再加入5毫升三乙胺,加热反应半小时。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得深棕色固体。产物用无水乙醇重结晶,得2-(2-甲基-3-吲哚基)甲基苯并咪唑-5-甲酸乙酯11.3克,产率77%。
实施例4:在三口烧瓶中加入50毫升二甲基甲酰胺,依次加入3,4-二氨基苯甲酸乙酯11.0克,2-甲基-3-吲哚乙酸8.3克,羰基二咪唑7.1克,置于微波反应器中,在480W功率下反应16分钟,再加入5毫升三乙胺,微波辐射反应2分钟。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得到褐色固体,用无水乙醇重结晶,得2-(2-甲基-3-吲哚基)甲基苯并咪唑-5-甲酸乙酯12.6克,产率为86%。
实施例5:在三口烧瓶中加入50毫升二甲基甲酰胺,依次加入4-甲基邻苯二胺11.5克,2-甲基-5-甲氧基-3-吲哚乙酸9.7克,羰基二咪唑7.1克,缓慢升温至130℃,回流反应3小时,再加入5毫升三乙胺,加热反应半小时。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得深棕色固体,用无水乙醇重结晶,得5-甲基-2-(2-甲基-5-甲氧基-3-吲哚基)甲基苯并咪唑14.1克,产率76.7%。
实施例6:在三口烧瓶中加入50毫升二甲基甲酰胺,依次加入4-甲基邻苯二胺11.5克,2-甲基-5-甲氧基-3-吲哚乙酸9.7克,羰基二咪唑7.1克,置于微波反应器中,在480W功率下反应16分钟,再加入5毫升三乙胺,微波辐射反应2分钟。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得深棕色固体,用无水乙醇重结晶,得5-甲基-2-(2-甲基-5-甲氧基-3-吲哚基)甲基苯并咪唑15.2克,产率82.7%。
实施例7:在三口烧瓶中加入50毫升二甲基甲酰胺,依次加入3,4-二氨基苯甲酸乙酯16.9克,2-甲基-5-甲氧基-3-吲哚乙酸9.7克,羰基二咪唑7.1克,缓慢升温至130℃,回流反应3小时,再加入5毫升三乙胺,加热反应半小时。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得深棕色固体,用无水乙醇重结晶,得2-(2-甲基-5-甲氧基-3-吲哚基)甲基苯并咪唑-5-甲酸乙酯15.3克,产率70.0%。
实施例8:在三口烧瓶中加入50毫升二甲基甲酰胺,依次加入3,4-二氨基苯甲酸乙酯16.9克,2-甲基-5-甲氧基-3-吲哚乙酸9.7克,羰基二咪唑7.1克,置于微波反应器中,在480W功率下反应13分钟,再加入5毫升三乙胺,微波辐射反应2分钟。反应结束后冷却至室温,将反应混合物不断搅拌下倾倒入200克碎冰中。用氢氧化钠溶液调pH值至9-10,静置,析出固体产物。抽滤,干燥得深棕色固体,用无水乙醇重结晶,得2-(2-甲基-5-甲氧基-3-吲哚基)甲基苯并咪唑-5-甲酸乙酯17.4克,产率79.9%。
Claims (6)
1.新型吲哚-苯并咪唑衍生物及其合成方法,以2-甲基-3-吲哚乙酸及其衍生物和邻苯二胺及其衍生物为原料,在较高沸点溶剂中或者不使用溶剂、缩合剂作用下,用加热或者微波照射的方法使其脱水环合生成亚甲基连接的吲哚-苯并咪唑衍生物,反应式如下所示:
。
2.如权利要求1中方法所述,式中取代基R1、R2、R3、R4、R5、R6、R7、R8分别为:H,F,Cl,Br,CF3,CCl3,CN,N(CH3)2,N(C2H5)2,NO2,SO3H,CH2R’,OR’,NHR’,COR’,COOR’,CONHR’;其中R’为H,CH3,CH2CH3,COCH3,F,Cl,Br,CF3,CCl3。
3.如权利要求1中方法所述,反应中2-甲基-3-吲哚乙酸及其衍生物与邻苯二胺及其衍生物的物料摩尔比为1∶0.5至1∶50;2-甲基-3-吲哚乙酸及其衍生物与溶剂的质量比为1∶1至1∶100;2-甲基-3-吲哚乙酸及其衍生物与缩合剂的质量比为1∶0.1至1∶10。
4.如权利要求1中方法所述,其特征在于,较高沸点溶剂为乙二醇,乙二醇一甲酯,乙二醇二甲酯,乙二醇一乙酯,乙二醇二乙酯,硝基乙烷,二甲基甲酰胺,二乙基甲酰胺,二甲亚砜,丙二醇,丙三醇,二甘醇,二苯基醚。
5.如权利要求1中方法所述,加热进行反应时反应时间为0.5~24小时,反应温度为80~250℃,或者微波辐射进行反应时反应时间为1~100分钟。
6.如权利要求1中方法所述,其特征在于,缩合剂为:N,N′-羰基二咪唑,二环己基碳二亚胺,多聚磷酸,1-(3-二甲氨基丙基)-3-乙基碳二亚胺,二异丙基碳二亚胺,1,1′-羰基二(1,2,4-三氮唑),4-二甲氨基吡啶,1,1′-羰基二吡咯,4,5-二氰基咪唑,氰代磷酸二乙酯,4-(4,6-二甲氧基三嗪)-4-甲基吗啉氯化物,1-(3-二甲氨基丙基)-3-乙基碳二亚胺。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410583377.4A CN104387371A (zh) | 2014-10-20 | 2014-10-20 | 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410583377.4A CN104387371A (zh) | 2014-10-20 | 2014-10-20 | 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104387371A true CN104387371A (zh) | 2015-03-04 |
Family
ID=52605347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410583377.4A Pending CN104387371A (zh) | 2014-10-20 | 2014-10-20 | 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104387371A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315262A (zh) * | 2015-11-28 | 2016-02-10 | 青岛科技大学 | 吲哚-3-羧酸苯并咪唑-2-甲酯衍生物及其合成 |
CN105585559A (zh) * | 2016-01-26 | 2016-05-18 | 青岛科技大学 | 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 |
CN106220611A (zh) * | 2016-08-08 | 2016-12-14 | 青岛科技大学 | 2‑(1h‑吲哚‑3‑基)‑1h‑苯并咪唑衍生物的新制备方法 |
CN107021959A (zh) * | 2017-05-02 | 2017-08-08 | 青岛科技大学 | 一类新型吲哚衍生物及其体外抗肿瘤活性 |
-
2014
- 2014-10-20 CN CN201410583377.4A patent/CN104387371A/zh active Pending
Non-Patent Citations (2)
Title |
---|
JULIE CHARTON ET AL.: "Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
王陆瑶等: "微波辐射下2-取代苯并咪唑衍生物库的平行合成", 《化学通报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315262A (zh) * | 2015-11-28 | 2016-02-10 | 青岛科技大学 | 吲哚-3-羧酸苯并咪唑-2-甲酯衍生物及其合成 |
CN105585559A (zh) * | 2016-01-26 | 2016-05-18 | 青岛科技大学 | 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 |
CN106220611A (zh) * | 2016-08-08 | 2016-12-14 | 青岛科技大学 | 2‑(1h‑吲哚‑3‑基)‑1h‑苯并咪唑衍生物的新制备方法 |
CN107021959A (zh) * | 2017-05-02 | 2017-08-08 | 青岛科技大学 | 一类新型吲哚衍生物及其体外抗肿瘤活性 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104387371A (zh) | 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 | |
Wang et al. | Microwave-assisted multi-component reaction in water leading to highly regioselective formation of benzo [f] azulen-1-ones | |
Zhang et al. | Silver-catalyzed intramolecular hydroamination of alkynes in aqueous media: Efficient and regioselective synthesis for fused benzimidazoles | |
WO2014183730A2 (zh) | 一种他达那非的制备方法 | |
Shaikh et al. | An efficient solvent-free synthesis of imidazolines and benzimidazoles using K 4 [Fe (CN) 6] catalysis | |
CN106189363A (zh) | 一类含2‑(2’‑羟基苯基)苯并咪唑衍生物合Cd(Ⅱ)的聚合金属配合物染料敏化剂及其制备方法和用途 | |
Nagawade et al. | TiCl₄ Promoted synthesis of benzimidazole derivatives | |
Yao et al. | A facile synthesis of tetrahydroimidazo [1, 2-a] pyridines and tetrahydrobenzo [b] imidazo [1, 2, 3-ij][1, 8] naphthyridines through NHC-catalyzed cascade annulations | |
CN103755659B (zh) | 6-肉桂酰基-2H-苯并[b][1,4]噁嗪-3(4H)-酮类化合物及其应用 | |
CN110885570B (zh) | 一种近红外染料的制备方法 | |
Lopez et al. | One-Pot Microwave Promoted Synthesis of 2-Aryl-1H-benzimidazoles Using Sodium Hydrogen Sulfite. | |
CN110818672A (zh) | 一种具有抗氧化作用的环丁烯酮类化合物及其制备方法 | |
Zhao et al. | A rapid and convenient synthesis of derivatives of imidazoles under microwave irradiation | |
CN102408377B (zh) | 一种苯并咪唑席夫碱及其合成方法 | |
Chen et al. | Synthesis of 8-oxoprotoberberines using acid-mediated cyclization or the Heck reaction | |
Akansha et al. | A Mild and Environmentally benign Synthesis of Benzimidazoles: Relevance to the pectin hetero Polysaccharide as a Catalyst | |
CN113402466A (zh) | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 | |
Jiang et al. | Reactions of α-Phenylglyoxylic Acids with ortho-Functionalized Anilines in Deep Eutectic Solvents: Selective Syntheses of 3-Aryl-2H-benzo [b][1, 4] oxazin-2-ones, 2-Arylbenzothiazoles, and 3-Arylquinoxalin-2 (1H)-ones | |
CN106966951B (zh) | 4-氟-2-甲基吲哚及其制备方法和应用 | |
CN106220611A (zh) | 2‑(1h‑吲哚‑3‑基)‑1h‑苯并咪唑衍生物的新制备方法 | |
CN105753862B (zh) | 一种3‑芳基吲哚嗪乙酸酯衍生物及其制备方法和应用 | |
CN107673991A (zh) | 一种席夫碱衍生物及其制备方法 | |
Wang et al. | Synthesis of novel indole-benzimidazole derivatives | |
Chikvaidze et al. | Some new derivatives of 5-aryl-, 2, 5-diaryl-and 2-ethoxycarbonyl-5-aryl-indoles. | |
Zhao et al. | Polyphosphoric acid catalyst for the one-pot synthesis of 3, 4-dihydropyrimidin-2 (1H)-ones by grinding under solvent-free conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150304 |